LQDA - Multiplikator Forward P/S Liquidia Corporation

Logo korporat perusahaan Liquidia Corporation (LQDA)

Logistics optimization for inhalation agents targeting rare pathologies provides Liquidia Corporation (LQDA) with high margins and stable sales. The expected revenue multiple visualizes this trend, where the parameter value equals 8.30. While its status as an innovator in pulmonary hypertension therapy strengthens the brand image, the ultimate success of the business relies heavily on the outcomes of patent litigation and regulatory timelines.

LQDA Liquidia Corp: Prakiraan rega marang pendapatan ing interval 04.07.2022 - 15.11.2026

Rincian analitis perusahaan Liquidia Corporation

- rega pasar lan target rega analis:
Bagan rega Liquidia Technologies|LQDA - Bagan rega target
- statistik kapitalisasi pasar:
Kapitalisasi pasar Liquidia Technologies|LQDA - Rega Tumbas Perusahaan
- statistik nilai buku emiten:
Aset Bersih saben Siji Saham Liquidia|LQDA - Nilai Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih liquidia.com|LQDA - Total Aset Perusahaan
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal Liquidia Corporation|LQDA - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal Liquidia Technologies|LQDA - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Liquidia Technologies|LQDA - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Liquidia|Indikator likuiditas cepet liquidia.com
- data bathi bisnis lan rasio investasi:
LQDA - Bathi pungkasan|Proyeksi bathi mangsa ngarep Liquidia Corporation|LQDA - Koefisien rega marang bathi|Rega marang bathi mangsa ngarep Liquidia Corp|LQDA - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Liquidia Corp|LQDA - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Liquidia|LQDA - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan liquidia.com|LQDA - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Liquidia Corporation
- data pendapatan lan penerimaan dodolan:
LQDA - Pendapatan dodolan perusahaan|Prakiraan volume dodolan Liquidia Corp|LQDA - Multiplikator P/S|Multiplikator forward rega marang pendapatan Liquidia Inc.|LQDA - Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur
Pambiji fundamental perusahaan:Liquidia Inc. LQDA
Sampel barang Liquidia Inc.

Amid prolonged legal disputes regarding Liquidia Corporation (LQDA) and its product launch, the projected P/S valuation reflects the level of investor confidence in the success of the commercial rollout. This indicator compares current market capitalization with expected sales volume, determining whether the scalability premium is overvalued relative to real future revenue prospects.

Analisis perusahaan pesaing

Multiplikator Forward P/S HLN (Haleon PLC)|Multiplikator Forward P/S Kenvue Corp KVUE|Verona Pharma PLC - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep jyongbio.com|LGND: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan AMRX|Rasio rega marang prakiraan pendapatan Perrigo Company|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Alvotech ALVO|Rasio rega marang prakiraan pendapatan Galapagos Genomics (GLPG)|ANIP: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S MNKD (MannKind Corp)|Rasio kapitalisasi marang dodolan sing dikarepake Amphastar (AMPH)|PCRX: Multiplikator forward rega marang pendapatan|SPRY - Multiplikator Forward P/S|Theravance Biopharma, Inc. (TBPH) - Rasio rega marang prakiraan pendapatan|AQST (Aquestive Therapeutics) - Rasio rega marang prakiraan pendapatan|SCPH (scpharmaceuticals.com) - Multiplikator Forward P/S|TECX: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Rega forward marang dodolan|Multiplikator Forward P/S EPRX (Eupraxia Pharmaceuticals)|Rega forward marang dodolan BHST|Invizyne Technologies - Multiplikator Forward P/S|oramed.com (ORMP) - Multiplikator forward rega marang pendapatan|ENTX (enterabio.com) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan HYFT|ABVC (ABVC BioPharma, Inc) - Multiplikator Forward P/S|Multiplikator Forward P/S cumberlandpharma.com|Rasio rega marang prakiraan pendapatan Quantum BioPharma (QNTM)|FibroGen (FGEN) - Prakiraan rega marang pendapatan|Multiplikator Forward P/S TELO (telomirpharma.com)|RANI - Multiplikator forward rega marang pendapatan|SNYR - Rasio rega marang prakiraan pendapatan|rallybio.com - Rasio rega marang pendapatan sing dikarepake|LEXX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Pulmatrix Inc|PTHL (Pheton Holdings) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Aptorum Group Limited APM|Rasio rega marang prakiraan pendapatan Lyra Therapeutics (LYRA)|Multiplikator forward rega marang pendapatan Impact BioMedical Inc IBO|Rasio rega marang prakiraan pendapatan tnfpharma.com TNFA|Rega forward marang dodolan YCBD|PainReform Ltd - Multiplikator Forward P/S|Altamira Therapeutics Ltd (CYTO) - Multiplikator forward rega marang pendapatan|lipella.com (LIPO) - Rasio rega marang prakiraan pendapatan|OptiNose (OPTN) - Multiplikator Forward P/S|PIRS (Pieris Pharmaceuticals Inc) - Multiplikator Forward P/S|PROC: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|Multiplikator Forward P/S Qilian International Corp (QLI)|ACELYRIN, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S tffpharma.com TFFP